Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Acromegaly

Trial Information

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Official Title: A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly

Summary

This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.

Phase: Phase 3

Sponsor: Novartis Pharmaceuticals

Overall Contacts:

Novartis Pharmaceuticals
+1 800-340-6843

Locations (62)

Country State City Zip Facility and Contact
United States California Los Angeles 90055 The Regents of the University of California
Anthony Heany, M.D.
310-267-4980

Anthony Heany, M.D.
Principal Investigator
United States Maryland Baltimore 21287 Johns Hopkins University School of Medicine
410-955-3921

Roberto Salvatori, M.D.
Principal Investigator
United States Pennsylvania Pittsburg 15212 Allegheny Endocrinology Associates
412-359-5143

Murray Gordon, M.D.
Principal Investigator
United States Texas Dallas 75390 University of Texas Southwest Medical Center
214-648-3494

Michael McPhaul, M.D.
Principal Investigator
United States Washington Seattle 98122 Swedish Medical Center Neuroscience Institute
206-320-2800

William Ludlam, M.D.
Principal Investigator
Argentina Buenos Aires Novartis Investigative Site
Belgium Bruxelles Novartis Investigative site
Belgium Leuven Novartis Investigative site
Belgium Wilrijk Novartis Investigative site
Brazil Botucatu Novartis Investigative Site
Brazil Campinas Novartis Investigative Site
Brazil Fortaleza Novartis Investigative Site
Brazil Joinville Novartis Investigative Site
Brazil Rio de Janeiro Novartis Investigative site
Brazil São Luiz Novartis Investigative Site
Brazil São Paulo Novartis Investigative site
Canada Edmondton Novartis Investigative Site
Canada Halifax Novartis Investigative Site
Canada Montreal Novartis Investigative Site
Canada Sherbrooke Novartis Investigative Site
Colombia Bogota Novartis Investigative Site
France Bron Novartis Investigative Site
France Dijon Novartis Investigative Site
France Kremlin Bicetre Novartis Investigative Site
France Lille Novartis Investigative Site
France Marseille Novartis Investigative Site
France Nantes Novartis Investigative Site
France Paris Novartis Investigative Site
France Pessac Novartis Investigative Site
France Rennes Novartis Investigative Site
France Toulouse Novartis Investigative Site
Germany Berlin Novartis Investigative Site
Germany Erlangen Novartis Investigative Site
Germany Essen Novartis Investigative Site
Germany Hamburg Novartis Investigative Site
Germany Leipzig Novartis Investigative Site
Germany München Novartis Investigative Site
Israel Petach Tikva Novartis Investigative Site
Italy Genova Novartis Investigative Site
Italy Messina Novartis Investigative Site
Italy Napoli Novartis Investigative Site
Italy Roma Novartis Investigative Site
Italy Torino Novartis Investigative Site
Norway Bergen Novartis Investigative Site
Norway Oslo Novartis Investigative Site
Poland Poznań Novartis Investigative Site
Poland Wroclaw Novartis Investigative Site
Poland Łódź Novartis Investigative Site
Romania Bucharest Novartis Investigative site
Russian Federation Barnaul Novartis Investigative Site
Russian Federation Moscow Novartis Investigative Site
Russian Federation Tyumen Novartis Investigative Site
Saudi Arabia Jeddah Novartis Investigative Site
Saudi Arabia Riyadh Novartis Investigative Site
Spain Alicante Novartis Investigative Site
Spain Barcelona Novartis Investigative Site
Spain Madrid Novartis Investigative Site
Spain Santiago de Compostela Novartis Investigative Site
Spain Sevilla Novartis Investigative Site
Turkey Antalya Novartis Investigative Site
Turkey Istanbul Novartis Investigative Site
Turkey Izmir Novartis Investigative Site

NCT ID:NCT01137682

Date Last Changed: June 7, 2013